期刊文献+

格列吡嗪控释片对2型糖尿病患者血管内皮功能的影响 被引量:2

Effects of Glipizide-XL on the Endothelium-dependent Relaxing Function of Brachi al Artery in Patients with Type 2 Diabetes Mellitus.
下载PDF
导出
摘要 目的 探讨格列吡嗪控释片对2型糖尿病患者血管内皮功能的影响。方法 76例2型糖尿病者,经2周洗脱期后,随机分为两组。一组4 0例应用格列吡嗪控释片;另一组36例应用格列本脲。根据达到目标血糖调整药物剂量,单药未能达标者加用阿卡波糖,治疗期12周。每位患者均采用高分辨率超声显像法,分别于治疗前后各进行一次右肱动脉血管内皮功能检测。结果 格列本脲组治疗前后肱动脉内径基础值、反应性充血及含服硝酸甘油后肱动脉内径变化,均无显著性差异[(3. 70±0 . 5 7)mm对(3 .72±0 . 5 9)mm ,(5 . 4 6±0 .82 ) %对(5 .70±0 .84 ) % ,(2 0 . 5±5 . 0 ) %对(2 0 . 1±5 . 1) % ,P >0 .0 5 ]。格列吡嗪控释片组治疗前后肱动脉内径基础值、含服硝酸甘油后肱动脉内径的变化,也无显著性差异[(3 .72±0 . 6 2 )mm对(3 .73±0 . 6 3)mm ,(19. 8±5. 5 ) %对(19. 9±5 . 8) % ,P >0 . 0 5 ];但反应性充血引起肱动脉内径变化,治疗前后具有非常显著性差异[(5. 6 7±0 .79) %对(9. 4 6±3 .81) % ,P <0 . 0 1]。结论 格列吡嗪控释片可能改善2型糖尿病者的血管内皮功能。 Objective To study the effect of glipizide-XL on en dothelium-dependent relaxing function in type 2 diabetic patients. Metho ds After 2 weeks' run-in, 76 patients with type 2 diabetes mellitus were randomly divided into two groups. They were administrated glipizide-XL(glipizid e-XL group) or glyburide(glyburide group) for 12 weeks. According to the status of blood glucose, some of them were added acarbose. Endothelium-dependent relaxi ng function of brachial artery was measured with B-mode ultrasound in all patien ts before and after treatment. Results In glyburide group, t here was no significant difference before and after treatment in baseline, respo nse to nitroglycerin and responsive congestion in brachial artery endothelium-de pendent relaxing function[(3.70±0.57)mm vs (3.72±0.59)mm,(5.46±0.82)% vs (5.70±0.84)%, (20.0±5.0)% vs(20.1±5.1)%,P>0.05 respectively ]. In glipizide-XL group, there was no significant difference before and after treatment in baseline and response to nitroglycerin in brachial artery endotheli um-dependent relaxing function[(3.72±0.62)mm vs (3.73±0.63)mm,(19.8±5 .5)% vs (19.9±5.8)%, respectively, P>0.05]. But there was significant difference in responsive congestion in brachial artery endothelium-dependent re laxing function before and after treatment[5.67±0.79)% vs (9.46±3.81)%, P<0.01]. Conclusions Treatment with glipizide-XL can improve endothelium function in patients with type 2 diabetes mellitus.
出处 《心脑血管病防治》 2005年第2期10-12,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
关键词 2型糖尿病 格列吡嗪控释片 内皮功能 Type 2 diabetes mellitus Glipizide-XL Endotheliu m-dependent relaxing function
  • 相关文献

参考文献10

  • 1Piero OB, Lilach OL, Amir L, et al. Endothelial Dysfunction: A Marker of Atherosclerotic Risk. Arterioscler Thromb Vasc Biol,2003,23(1):168-175.
  • 2Report of WHO Consultation, Diagnosis and classification of diabetea mellitus. Genveva: WHO,1999,59p.
  • 3Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 1992,340:1111-1115.
  • 4Calles-Escandon J, Cipolla M. diabetes and endothelial dyfunction: a clinical perspective. Endocr Rev, 2001,22(1):36-52.
  • 5Nesto R. CHD: a major burden i type 2 diabetes. Acta Diabetelol, 2001,38(Suppl)1:s3-8.
  • 6Vehkavaara S, Makimattilas S, Schlenzka A, et al. Insulin therapy improves endothelial function in type 2 diabetes. Arteriosclar Thromb Vasc Biol, 2000,20:545-550.
  • 7UKPDS Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of cmoplications in patients with type 2 diabetes. Lancet, 1998, 352:837-853.
  • 8李秀钧.2型糖尿病防治策略的革命——从降糖治疗到全面防治心血管危险因素[J].中华内科杂志,2002,41(4):217-218. 被引量:28
  • 9Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas:lessons from studies of clonedK(ATP) channels. J Diabetes Complications, 2000,14(4):192-196.
  • 10Shiling H, Shuya W, Barbara Fanelli, et al. Pancreatic β-Cell KATP Channel Activity and Membrane-Binding Studies with Nateglinide:A Comparison with Sulfonylureas and Repaglinide. J Pharmacol Exp Ther, 2000,293(2):444-452.

二级参考文献11

  • 1Colwell JA. Multifactorial aspects of treatment of the type 2 diabetic patient. Metabolism, 1997, 46Suppl 1: 1-4.
  • 2American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care, 2001, 24Suppl 1: S25-27.
  • 3American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2001, 24Suppl 1: S28-31.
  • 4Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest, 2000, 106: 1305-1307.
  • 5Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes, 2001, 50Suppl 1: S118-121.
  • 6Cnop M, Hannaert JC, Hoorens A, et al. Inverse relationship between cytotoxicity of fatty acids in pancneatic islet cells and cellular triglyceride accumulation. Diabetes, 2001, 50: 1771-1771.
  • 7McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes, 2001, 50Suppl 2: 6-7.
  • 8Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature, 2001, 489 : 307-312.
  • 9American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care, 2000, 23Suppl 1: S61-62.
  • 10American Diabetes Association. Smoking and diabetes. Diabetes Care, 2000, 23Suppl 1: S63-64.

共引文献27

同被引文献8

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部